Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is
a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. It
has potent antiproliferative effects in vitro and is active in tumor
models in vivo. While surveying the effect of flavopiridol on cell cyc
le progression in different cell types, we discovered that hematopoiet
ic cell lines, including SUDHL4, SUDHL6 (B-cell lines), Jurkat, and MO
LT4 (T-cell lines), and HL60 (myeloid), displayed notable sensitivity
to flavopiridol-induced apoptosis. For example, after 100 nmol/L for 1
2 hours, SUDHL4 cells displayed a similar degree of DNA fragmentation
to that shown by the apoptosis-resistant PC3 prostate carcinoma cells
only after 3,000 nmol/L for 48 hours. After exposure to 1,000 nmol/L f
lavopiridol for 12 hours, typical apoptotic morphology was observed in
SUDHL4 cells, but not in PC3 prostate carcinoma cells despite compara
ble potency (SUDHL4:120 nmol/L; PC3: 203 nmol/L) in causing growth inh
ibition by 50% (IC50). Flavopiridol did not induce topoisomerase I or
II cleavable complex activity. A relation of p53, bcl2, or bar protein
levels to apoptosis in SUDHL4 was not appreciated. While flavopiridol
caused cell cycle arrest with decline in CDK1 activity in PC3 cells,
apoptosis of SUDHL4 cells occurred without evidence of cell cycle arre
st. These results suggest that antiproliferative activity of flavopiri
dol (manifest by cell cycle arrest) may be separated in different cell
types from a capacity to induce apoptosis. Cells from hematopoietic n
eoplasms appear in this limited sample to be very susceptible to flavo
piridol-induced apoptosis and therefore clinical trials in hematopoiet
ic neoplasms should be of high priority. (C) 1998 by The American Soci
ety of Hematology.